Debra M. Foster, BSc, spent 11 years as an RN in the adult critical care area. Thereafter, Debra joined the critical care clinical research team at Toronto General Hospital. She was project lead for a multi-national, multi-center clinical trial - the MEDIC study. The data was used for a successful 510(k) de novo submission to the FDA for the Endotoxin Activity Assay (EAA). It was the first IVD for sepsis. Debra went on to follow the device to its commercial partner, Spectral Medical, Inc. She became VP of Clinical Development in 2011.  Debra led many clinical research projects, including the MEDIC, EUPHRATES, and TIGRIS clinical trials, aimed at endotoxin in critical illness. Currently, Debra is a clinical consultant for Spectral Medical. She has lectured to medical professionals on the topics of sepsis, endotoxin, and clinical trials for sepsis and has been a co-author of more than 50 articles in peer-reviewed journals.